基线同步腺瘤负荷对异时性进展性肿瘤风险的影响
一项台湾多中心前瞻性队列研究纳入730例常规高危腺瘤患者,随访平均2.4年,81例(11.1%)发生异时性进展性结直肠肿瘤。单发高危腺瘤较3-4个低危腺瘤未显著增加风险,但高危腺瘤合并同步低危或高危腺瘤时风险显著递增,呈剂量反应趋势。
要点
- 常规高危人群异时性进展性肿瘤风险高度异质,由基线同步腺瘤负荷驱动。
- 单发高危腺瘤与3-4个低危腺瘤相比风险无显著差异。
- 高危腺瘤合并同步腺瘤者风险递增,应个性化缩短监测间隔。
核心结论
- 常规高危人群异时性进展性结直肠肿瘤风险高度异质,主要由基线同步肿瘤负荷决定。
研究设计与样本
- 前瞻性队列研究,使用台湾多中心试验(NCT03373136)数据,纳入730例常规高危参与者(3-10个低危腺瘤或任何高危腺瘤)。
主要发现
- 730例中81例(11.1%)发生异时性进展性结直肠肿瘤,平均随访2.4年。
- 单发高危腺瘤较3-4个低危腺瘤的aIRR为2.02(95%CI 0.83-4.90),无显著差异。
- 高危腺瘤合并同步低危腺瘤aIRR为2.56(95%CI 1.24-5.39),合并同步高危腺瘤aIRR为3.93(95%CI 1.77-8.73),趋势P=0.001。
- 采用更严格的改良进展性腺瘤标准,合并同步高危腺瘤时严重异时性结局风险aIRR为5.23(95%CI 1.50-18.22)。
关键数值与推荐
- 常规高危定义:3-10个低危腺瘤或任何高危腺瘤。
- 以3-4个低危腺瘤为参照计算aIRR。
临床怎么用
- 对高危腺瘤合并同步腺瘤的患者,可考虑缩短监测间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: and study aim: Individuals classified as high-risk at initial colonoscopy face an elevated risk of metachronous advanced colorectal neoplasms (meta-ACRN), but risk heterogeneity within this group remains unclear. We aimed to stratify meta-ACRN risk among high-risk individuals based on their synchronous neoplastic burden. METHODS: This prospective cohort study used data from a Taiwanese multicenter trial (NCT03373136). We included participants with conventional high-risk findings (3-10 low-risk adenomas [LRAs] or any high-risk adenoma [HRA]). The primary outcome was meta-ACRN incidence. Adjusted incidence rate ratios (aIRRs) were calculated using multivariable Poisson regression, stratifying patients by baseline synchronous burden, with the 3-4 LRAs group as reference. RESULTS: Among 730 participants undergoing surveillance (mean follow-up 2.4 years), 81 (11.1%) developed meta-ACRN. A single HRA did not significantly increase meta-ACRN risk compared with 3-4 LRAs (aIRR 2.02; 95% confidence interval (CI) 0.83-4.90). However, risk escalated significantly when the index HRA was accompanied by synchronous LRA(s) (aIRR 2.56; 95% CI 1.24-5.39) or synchronous HRA(s) (aIRR 3.93; 95% CI 1.77-8.73) ( P for trend = 0.001). Furthermore, applying a more severe modified advanced adenoma criteria, an identical dose-response pattern emerged, culminating in a >5-fold increased risk of severe metachronous outcomes (aIRR 5.23; 95% CI 1.50-18.22) when accompanied by synchronous HRA(s). DISCUSSION: Meta-ACRN risk within the conventional high-risk population is highly heterogeneous and driven primarily by baseline synchronous neoplastic burden. Surveillance intervals should be personalized, reserving shorter intervals for patients with advanced lesions accompanied by synchronous adenomas.
引用
- Chang WY, Chang LC, Chou CK, et al. Impact of Baseline Synchronous Adenoma Burden on the Risk of Metachronous Advanced Neoplasia. Am J Gastroenterol. 2026. PMID: 42690927. doi:10.14309/ajg.0000000000004197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。